Moderna-Merck mRNA vaccine shows promise in delaying melanoma recurrence
TL;DR Summary
Moderna and Merck report interim Phase 3 results suggesting their personalized mRNA cancer vaccine Intismeran, used with Keytruda after melanoma surgery, may delay cancer recurrence in high-risk patients; data have not yet been peer‑reviewed and will be presented at a medical meeting and shared with regulators as the trial continues to assess overall survival.
- Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma NBC News
- Cancer treatment could face landmark moment with promising vaccine The Washington Post
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano Business Wire
- Moderna, Merck mRNA cancer vaccine prevents melanoma from returning thehill.com
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
2 min
vs 3 min read
Condensed
89%
513 → 54 words
Want the full story? Read the original article
Read on NBC News